China Biopharmaceuticals Holdings, Inc. , a leading Chinese pharmaceutical company focused on the development, manufacturing and marketing of innovative drugs in China, today announced its financial results for the year ended December 31, 2006.

Revenues for the year ended December 31, 2006 increased 9.5% to $26 million compared to $23.7 million in 2005. Revenue primarily increased due to the accretive effects of the full-year results of Erye and the Enshi acquisition, which occurred in June 2006 that generated $22.6 million and $2.9 million respectively. Erye increased sales through the introduction of new generic products in 2006. Keyuan, the Company's third subsidiary, generated $452,052 in sales for 2006.

Source:佚名